K. Wilson

发表

Cutaneous malignant melanoma

K. Wilson, 1994 .

Adjuvant interferon alfa for melanoma.

K. Wilson, A. Attwell, 2010, Current oncology.

Raltitrexed: optimism and reality

K. Wilson, Suzanne C. Malfair Taylor, 2009, Expert opinion on drug metabolism & toxicology.

Regarding Chan et al. IJROBP 1999;45:265-270.

K. Wilson, J. T. Lim, 2000, International journal of radiation oncology, biology, physics.

Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.

M. E. Kirk, M. Levitt, J. Pater, 1987, Cancer treatment reports.

Primary cutaneous malignant melanoma: experience of the British Columbia Cancer Agency from 1972 to 1981.

K. Wilson, V. Carmichael, 1992, Canadian journal of surgery. Journal canadien de chirurgie.

Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.

E. Eisenhauer, R. Stuart-Harris, D. Raghavan, 1986, Cancer treatment reports.

A predictive index of cure versus no cure in advanced ovarian carcinoma patients--replacement of second-look laparotomy as a diagnostic test.

M. E. Kirk, A. Willan, M. Levitt, 1987, Gynecologic oncology.

Regression of follicular lymphoma with Devil’s Claw: coincidence or causation?

K. Wilson, 2009, Current oncology.

CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma (DLBCL).

R. Gascoyne, L. Sehn, J. Connors, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose interferon versus GM2 vaccine in high-risk malignant melanoma.

K. Wilson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma

E. Eisenhauer, R. Wierzbicki, N. Murray, 1988, Investigational New Drugs.

The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer

K. Wilson, J. Barnett, A. Shah, 2009, Current oncology.

Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.

E. Eisenhauer, P. Band, K. Pritchard, 1986, Cancer treatment reports.

Postoperative chemoradiotherapy helps in gastric adenocarcinoma

K. Wilson, 2002, BMJ : British Medical Journal.

Spontaneous splenic rupture and pseudo-hyperkalaemia in chronic lymphatic leukaemia

K. Wilson, 1976 .

Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.

N. Le, J. Spinelli, J. Ragaz, 1997, The New England journal of medicine.

Metastatic leydig cell tumor of the testis report of three cases and review of the literature

J. Grem, D. Trump, K. Gilchrist, 1986, Cancer.

Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience

S. Gill, B. Pharm., K. Wilson, 2007, Cancer investigation.

Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial.

John J Spinelli, Karen Gelmon, J. Spinelli, 2005, Journal of the National Cancer Institute.

Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.

K. Pritchard, M. Trudeau, D. Stewart, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Locoregional first recurrence after mastectomy: prospective cohort studies with and without immediate chemotherapy.

V. Basco, B. Haylock, K. Wilson, 2000, International journal of radiation oncology, biology, physics.

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.

R. Gascoyne, L. Sehn, J. Connors, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Curative treatment for esophageal cancer: Vancouver Island Cancer Centre experience from 1993 to 1998.

K. Wilson, G. Dewar, Amanda G. Wilson, 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation.

K. Wilson, J. T. Lim, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Immune toxicities and long remission duration after ipilimumab therapy for metastatic melanoma: two illustrative cases.

K. Wilson, H. Assi, Hazem Assi, 2013, Current oncology.

Spontaneous pneumothorax: a ten-year study.

K. Wilson, 1970, Military medicine.

Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.

E. Warner, L. Yelle, J. Latreille, 1993, The New England journal of medicine.

Missed diagnosis: the shrinking man revisited.

M. Brigden, K. Wilson, 1983, Canadian Medical Association journal.

Adjuvant systemic therapy and survival after breast cancer.

K. Gelmon, J. Ragaz, I. Olivotto, 1994, The New England journal of medicine.

Clinical Activity of Celecoxib in Metastatic Malignant Melanoma

K. Wilson, 2006, Cancer investigation.

CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma

R. Gascoyne, L. Sehn, J. Connors, 2007, Leukemia & lymphoma.

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

R. Gascoyne, L. Sehn, J. Connors, 2005 .

Clinical activity of celecoxib (CXB) in metastatic malignant melanoma (MMM)

K. Wilson, S. Allan, 2005 .

First-line mitoxantrone chemotherapy for advanced breast cancer.

A. Paterson, K. Wilson, 1986, Cancer treatment reports.

Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma.

M. E. Kirk, J. Carmichael, A. Willan, 1988, Gynecologic oncology.

The relationship between the absolute granulocyte count, platelet count and total leukocyte count in cancer chemotherapy patients.

M. Brigden, K. Wilson, J. Spinelli, 1991, Clinical and investigative medicine. Medecine clinique et experimentale.

Cyclic alternating chemotherapy for small cell carcinoma of the lung.

N. Murray, K. Wilson, G. Gudauskas, 1985, Cancer treatment reports.

Melanoma in Britain and British Columbia

K. Wilson, 1994, BMJ.

Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy.

J. Hainsworth, B. Zee, J. Krook, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rational Choice of Antiemetic Agents during Cancer Chemotherapy.

M. Brigden, K. Wilson, J. Barnett, 1983, Canadian family physician Medecin de famille canadien.

Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada.

D. Osoba, F. Shepherd, A. Willan, 1987, Annals of internal medicine.

Neoadjuvant hormone therapy and external beam radiation for localized prostate cancer: Vancouver Island Cancer Centre experience.

K. Wilson, A. Alexander, C. Ludgate, 2000, The Canadian journal of urology.

Is tremelimumab beneficial in advanced melanoma?

R. Kotb, K. Wilson, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.